Profound Medical (TSE:PRN) Stock Price Up 2.3% – Still a Buy?

Profound Medical Corp. (TSE:PRN) shares traded up 2.3% during mid-day trading on Tuesday . The company traded as high as C$9.82 and last traded at C$9.82. 2,101 shares changed hands during trading, a decline of 87% from the average session volume of 15,850 shares. The stock had previously closed at C$9.60.

Profound Medical Trading Up 2.3%

The stock has a market capitalization of C$356.84 million, a P/E ratio of -7.92 and a beta of 1.26. The stock’s fifty day moving average price is C$9.59 and its 200 day moving average price is C$9.47. The company has a debt-to-equity ratio of 12.56, a current ratio of 6.56 and a quick ratio of 14.98.

Profound Medical (TSE:PRN) last announced its quarterly earnings data on Thursday, May 7th. The company reported C$0.26 earnings per share for the quarter. The company had revenue of C$7.42 million during the quarter. Profound Medical had a negative net margin of 206.94% and a negative return on equity of 78.75%. Research analysts forecast that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.